Back to top

Image: Bigstock

Pacira Pharmaceuticals, Inc.

Read MoreHide Full Article

The company’s efforts to expand Exparel's label to boost sales in oral surgery and chronic pain are encouraging. The company reported positive topline results for Exparel from its phase IV study in total knee arthroplasty (TKA). The company also collaborated with DePuy Synthes which is expected to significantly expand use of Exparel across a broad range of surgical procedures. Pacira is looking to expand Exparel's label in the animal health market as well. Its share price has outperformed the broader industry year to date. However, Pacira’s sole dependence on Exparel for top-line growth is concerning. We are also concerned about the lack of other late-stage candidates in the company’s pipeline. Estimate movement has been mixed lately ahead of the Q1 earnings results. Pacira has a positive record of earnings surprises in recent quarters.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Pacira BioSciences, Inc. (PCRX) - free report >>